HIV infection - A risk factor for osteoporosis

Journal of Acquired Immune Deficiency Syndromes

Volumn 33, Issue 3, 2003, Pages 281-291

  Thomas, Joegi ^a,b   Doherty, Sheelagh M ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

^b HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Antiretroviral therapy; Bone mineral density; HIV; Osteopenia; Osteoporosis

Indexed keywords

ALKALINE PHOSPHATASE; ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; BICARBONATE; BISPHOSPHONIC ACID DERIVATIVE; INTERLEUKIN 6; PROTEINASE INHIBITOR; TESTOSTERONE; TUMOR NECROSIS FACTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALKALINE PHOSPHATASE BLOOD LEVEL; BICARBONATE BLOOD LEVEL; BODY WEIGHT; BONE DENSITY; BONE MINERAL; BONE REMODELING; CLINICAL FEATURE; DUAL ENERGY X RAY ABSORPTIOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPHOTOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCALCEMIA; HYPOCALCEMIA; MEDICAL LITERATURE; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCREENING TEST; STANDARD; SURVIVAL TIME; TUMOR NECROSIS; VASCULAR NECROSIS; VIRUS LOAD;

EID: 0037488471     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200307010-00001     Document Type: Review

References (106)

1. Marcus R. Exercise and the regulation of bone mass. Arch Intern Med. 1989;149:2170-2171.
2. Jackson JA, Kleerekoper M. Osteoporosis in men: diagnosis, pathophysiology and prevention. Medicine (Baltimore). 1990;69:137-152.
3. Paton NIJ, Macallan DC, Griffin GE, et al. Bone mineral density in patients with human immunodeficiency virus infection. Calcif Tissue Int. 1997;61:30-32.
4. Serrano S, Marinoso ML, Soriano JC, et al. Bone remodelling in human immunodeficiency virus -1 infected patients. A histomorphometric study. Bone. 1995;16:185-191.
5. Hernandez Quero J, Ortego Centeno N, Munoz-Torres M, et al. Alteration in bone turnover in HIV-positive patients. Infection. 1993;21.
6. Mellert W, Kleinschmidt A, Schmidt J, et al. Infection of human fibroblasts and osteoblast-like cells with HIV-1. AIDS. 1990;4:527-535.
7. Salzman NP, Psallidopoulos M, Prewett AB, et al. Detection of HIV in bone allografts prepared from AIDS autopsy tissue. Clin Orthop. 1993;292:384-390.
8. Buck BE, Resnick L, Shah SM, et al. Human immunodeficiency virus cultured from bone. Implications for transplantation. Clin Orthop. 1989;251:249-253.
9. Hernandez Quero J, Ortego Centeno N, Munoz-Torres M, et al. Alteration in bone turnover in HIV-positive patients. Infection. 1993;21:220-222.
10. Guaraldi G, Ventura P, Albuzza M, et al. Pathological fractures in AIDS patients with osteopenia and osteoporosis induced by antiretroviral therapy. AIDS. 2001;15:137-141.
11. Stephens EA, Das R, Madge S, et al. Symptomatic osteoporosis in two young HIV-positive African women. AIDS. 1999;13:2605-2506
12. Tebas P, Powderly WG, Claxton S, et al. Accelerated bone and mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS. 2000;14:63-67.
13. Carr A, Miller J, Eisman JA, et al. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS. 2001;15:703-709.
14. Fairfield WP, Finkelstein JS, Klibanski A, et al. Osteopenia in eugonadal men with acquired immune deficiency syndrome wasting syndrome. J Clin Endocrinol Metab. 2001;86:2020-2026.
15. Moorea AL, Vashishtb A, Sabina CA, et al. Reduced bone mineral density in HIV-positive individuals. AIDS. 2001;15:1731-1733.
16. Nolan D, Upton R, McKinnon E, et al. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS. 2001;15:1275-1280
17. Brown T, Timpone J, Ruppe M, et al. Bone loss associated with abnormalities in glucose metabolism in HIV patients on protease inhibitors. 9th Conference on Retroviruses and Opportunistic Infections; Seattle; February 2002.
18. Mondy K, Lassa-Claxton S, Hoffman M, et al. Longitudinal evolution of bone mineral density and bone markers in HIV-infected individuals. 9th Conference on Retroviruses and Opportunistic Infections; Seattle; February 2002.
19. Chang K, Kim J, Hong S, et al. Does race influence bone mineral density in HIV-infected individuals receiving HAART? 8th Conference on Retroviruses and Opportunistic Infections. Chicago; February 2001.
20. Gold J, Pocock N, Li Y, et al. Bone mineral density abnormalities in patients with HIV infection. J Acquir Immune Defic Syndr. 2002;30:131-132.
21. Loiseau-Peres S, Delaunay C, Poupon S, et al. Osteopenia in patients infected by the human immunodeficiency virus. A case control study. Joint Bone Spine. 2002;69:482-485.
22. Arnsten JH, Freeman R, Santoro N, et al. Bone mineral density and protease inhibitor use in older HIV-infected women. 9th Conference on Retroviruses and Opportunistic Infections; Seattle; February 2002.
23. Amiel C, Ostertag A, Lajeunie E, et al. Bone mineral density, lipodystrophy and bone metabolism markers in treated and nontreated HIV+ patients. 9th Conference on Retroviruses and Opportunistic Infections; Seattle; February 2002.
24. Knobel H, Guelar A, Valdecillo G, et al. Osteopenia in HIV-infected patients. Is it the disease or is it the treatment. 8th Conference on Retroviruses and Opportunistic Infections; Chicago; February 2001.
25. Negredo E, Gel S, Arisa ER, et al. Bone mineral density (BMD) in HIV-1-infected patients. 8th Conference on Retroviruses and Opportunistic Infections; Chicago; February 2001.
26. Lawal A, Engelson E, Wang S, et al. Equivalent osteopenia in HIV-infected subjects studied before and during the era of HAART. 8th Conference on Retroviruses and Opportunistic Infections; Chicago; February 2001.
27. Visser M, Kiel DP, Langlois J, et al. Muscle mass and fat mass in relation to bone mineral density in very old men and women: the Framingham Heart Study. Appl Radiat Isot. 1998;49:745-747.
28. Kotler DP, Tierney AR, Wang J, et al. Magnitude of body cell mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr. 1989;50:444-447.
29. Lipsky JJ. Abnormal fat accumulation in patients with HIV-1 infection. Lancet. 1998;351:847-848.
30. McDermott AY, Shevitz A, Knox T, et al. Effect of highly active antiretroviral therapy on fat, lean and bone mass in HIV-positive men and women. Am J Clin Nutr. 2001;74:679-686.
31. Huang JS, Wilke SJ, Sullivan MP, et al. Reduced bone density in androgen deficient women with acquired immune deficiency syndrome wasting. J Clin Endocrinol Metab. 2001;86:3533-3539.
32. Grinspoon SK, Bilezikian JP. HIV disease and the endocrine system. N Engl J Med. 1992;327:1360-1365.
33. Sellmeyer DE, Grunfeld C. Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome. Endocr Rev. 1996;17:518-532.
34. Hofbauer LC, Heufelder AE. Endocrine implications of human immunodeficiency virus infection. Medicine (Baltimore). 1996;75:262-278.
35. Kong YY, Feige U, Sarosi I, et al. Activated T cells regulated bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999;402:304-309.
36. Lahdevirta K, Maury CPJ, Teppo AM, et al. Elevated levels of circulating cachectin/tumour necrosis factor in patients with acquired immune deficiency syndrome. Am J Med. 1988;85:289-291.
37. Breen EC, Rezai AR, Nakajima K, et al. Infection with HIV is associated with elevated IL-6 levels and production. J Immunol. 1990;144:480-484.
38. Manolagas SC, Jika RL. Bone marrow, cytokines, and bone remodelling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med. 1995;332:305-311.
39. Carr A, Miller J, Law M, et al. A syndrome of lipoatrophy, lactic acidemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor related lipodystrophy syndrome. AIDS. 2000;14:F25-F32.
40. Chatta G, Arieff AI, Cummings C, et al. Lactic acidosis complicating the acquired immunodeficiency syndrome. Ann Intern Med. 1993;118:37-39.
41. Boubaker K, Sudre P, Flepp M, et al. Hyperlactatemia and antiretroviral therapy in the Swiss HIV Cohort Study [abstract 57]. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco; January 2000.
42. Lendru E, Christeff N, Patey O, et al. Alteration of tumour necrosis factor alpha T-cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome. Blood. 2000;95:3191-3198.
43. Cleric M, Trabattoni D, Piconi S, et al. A possible role for cortisol/anticortisol imbalance in the progression of HIV. Psychoneuroendocrinology. 1997;22(suppl 1):S27-S31.
44. Aukrust P, Haug CJ, Ueland T, et al. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalisation of the bone-remodelling process during highly active antiretroviral therapy. J Clin Endocrinol Metab. 1999;84:145-150.
45. Grinspoon S, Cocoran C, Lee K, et al. Loss of lean body mass and muscle mass correlates with androgen levels in hypogonadal men with HIV and wasting. J Clin Endocrinol Metab. 1996;81:4051-4058.
46. Mulligan K, Grunfeld C, Hellerstein MK, et al. Anabolic effects of recombinant insulin-like growth factor-1 in cachectic patients with HIV. J Clin Endocrinol Metab. 1993;77:956-962.
47. Hartman ML, Veldhuris JD, Johnson ML, et al. Augmented growth hormone (GH) secretory burst frequency and amplitude mediate enhanced GH secretion during a two day fast in normal men. J Clin Endocrinol Metab. 1992;74:757-765.
48. Dusso A. Protease inhibitors inhibit in vitro conversion on 25(OH)-vitamin D to 1,25 (OH)2-vitamin D [abstract 030]. 2nd International Workshop on Adverse Drug Interactions and Lipodystrophy; Toronto; September 2000.
49. Varnasi SS, Francis RM, Berger CE, et al. Mitochondrial DNA deletion associated oxidative stress and severe male osteoporosis. Osteoporos Int. 1999;10:143-149.
50. Papiha SS, Rathod H, Briceno I, et al. Age related somatic mitochondrial DNA deletion in bone. J Clin Pathol. 1998;51:117-120.
51. Claxton S, Demarco D, Powderly WG, et al. Circulating leptin and lactate levels are not associated with osteopenia in HIV-infected men. 8th Conference on Retroviruses and Opportunistic Infections; Chicago; February 2001.
52. Carr A, Miller J, Law M, et al. A syndrome of lipoatrophy, lactic acidemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor related lipodystrophy syndrome. AIDS. 2000;14:F25-F32.
53. Chatta G, Arieff AI, Cummings C, et al. Lactic acidosis complicating the acquired immunodeficiency syndrome. Ann Intern Med. 1993;118:37-39.
54. Boubaker K, Sudre P, Flepp M, et al. Hyperlactatemia and antiretroviral therapy in the Swiss HIV Cohort Study [abstract 57]. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco; January 2000.
55. Mellert W, Kleinschmidt A, Schmidt J, et al. Infection of human fibroblasts and osteoblast-like cells with HIV-1. AIDS. 1990;4:527-535.
56. Salzman NP, Psallidopoulos M, Prewett AB, et al. AIDS autopsy tissue. Clin Orthop. 1993;292:384-390.
57. Buck BE, Resnick L, Shah SM, et al. Human immunodeficiency virus cultured from bone. Implications for transplantation. Clin Orthop. 1989;251:249-253.
58. Marcus R. Exercise and the regulation of bone mass. Arch Intern Med. 1989;149:2170-2171.
59. Jackson JA, Kleerekoper M. Osteoporosis in men: diagnosis, pathophysiology and prevention. Medicine (Baltimore). 1990;69:137-152.
60. Lawal A, Engelson E, Wang S, et al. Effect of growth hormone on osteopenia in HIV+ patients. 8th Conference on Retroviruses and Opportunistic Infections; Chicago; February 2001.
61. Lawal A, Engelson E, Wang S, et al. Effect of oxandrolone upon bone mineral content in malnourished HIV+ patients. 8th Conference on Retroviruses and Opportunistic Infections; Chicago; February 2001.
62. McNurlan MA, Garlick PJ, Frost RA, et al. Albumin synthesis and bone collagen formation in human immunodeficiency virus-positive subjects: differential effects of growth hormone administration. J Clin Endocrinol Metab. 1998;83:3050-3055.
63. Teichmann J, Stephan E, Discher T, et al. Changes in calciotropic hormones and biochemical markers of bone protection in patients with human immunodeficiency virus infection. Metabolism. 2000;49:1134-1139.
64. Abu EO, Horner A, Kusec V, et al. The localisation of androgen receptors in human bone. J Endocrinol Metab. 1997;82:3493-3497.
65. O'Brien K, Razavi M, Henderson RA, et al. Bone mineral content in girls perinatally infected with HIV. Am J Clin Nutr. 2001;73:821-826.
66. Mankin HJ. Nontraumatic necrosis of bone (osteonecrosis). N Engl J Med. 1992;326:1473-1479.
67. Rademaker J, Dobro JS, Solomon G. Osteonecrosis and human immunodeficiency virus infection. J Rheumatol. 1997;24:601-604.
68. Meyer D, Behrens G, Schmidt RE, et al. Osteonecrosis of the femoral head in patients receiving HIV protease inhibitors [letter]. AIDS. 1999;13:1147-1148.
69. Glesby MJ, Hoover DR, Vaamonde CM. Osteonecrosis in patients infected with human immunodeficiency virus: a case control study. J Infect Dis. 2001;184:519-523.
70. Belmonte MA, Garcia-Portales R, Domenech I, et al. Avascular necrosis of bone in human immunodeficiency virus infection and antiphospholipid antibodies. J Rheumatol. 1993;20:1425-1428.
71. Casoso RT, Zion LI, Groopman JE. Anticardiolipin antibodies associated with HTLV-III infection. Br J Haematol. 1987;65:495-498.
72. Kuehn EW, Anders HJ, Bogner JR, et al. Hypocalcemia in HIV infection and AIDS. J Intern Med. 1999;245:69-73.
73. 3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab. 1998;83:3832-3898.
74. Wharton JM, Coleman DL, Wofsy CB, et al. Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immune deficiency syndrome. A prospective randomised trial. Ann Intern Med. 1986;105:37-44.
75. Peter SA. Disorders of serum calcium in acquired immune deficiency syndrome. JAMA. 1992;252:1152-1159.
76. Haug CJ, Muller F, Aukrust P, et al. Disseminated Mycobacterium avium complex in AIDS: immunopathogenetic significance of an activated tumour necrosis factor system and depressed serum levels of 1,25-dihydroxyvitamin D. J Infect Dis. 1996;173:259-262.
77. Perazella MA, Brown E. Electrolyte and acid base disorders associated with AIDS: an etiologic review. J Gen Intern Med. 1994;9:232-236.
78. Youle MS. Severe hypocalcemia in AIDS patients treated with foscarnet and pentamidine. Lancet. 1988;331:1455-1456.
79. Palestine AG, Polis MA, De Smet MD, et al. A randomised controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med. 1991;115:665-673.
80. Jacobson MA, Gambertoglio JG, Aweeka FT, et al. Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. J Clin Endocrinol Metab. 1991;72:1130-1135.
81. Shah GM, Alvarado P, Kirschenbaum MA. Symptomatic hypocalcemia and hypomagnesemia with renal magnesium wasting associated with pentamidine therapy in a patient with AIDS. Am J Med. 1990;89:380-382.
82. Wharton JM, Coleman DL, Wofsy CB, et al. Trimethoprim-sulphamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquire immune deficiency syndrome. A prospective randomised trial. Ann Intern Med. 1986;105:37-44.
83. Zaloga GP, Chernow B, Eil C. Hypercalcemia and disseminated cytomegalovirus infection in the acquired immunodeficiency syndrome. Ann Intern Med. 1985;102:331-333.
84. Fallatah S, Halim MA, Ellis ME. Hypercalcemia associated with cytomegalovirus infection in the acquired immunodeficiency virus syndrome. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8:101-102.
85. Ahmed B, Jaspen JB. Hypercalcemia in a patient with AIDS and Pneumocystis carinii pneumonia. Am J Med Sci. 1993;306:313-316.
86. Delahunt JW, Romeril KE. Hypercalcemia in a patient with the acquired immunodeficiency syndrome and Mycobacterium avium intracellulare infection. J Acquir Immune Defic Syndr. 1994;7:871-872.
87. Aly ES, Baig M, Khanna D, et al. Hypercalcemia: a clue to Mycobacterium avium intracellulare infection in a patient with AIDS. Int J Clin Pract. 1999;53:227-228.
88. Spindel SJ, Hamill RJ, Georghiou PR, et al. Vitamin D mediated hypercalcemia in fungal infection. Am J Med Sci. 1995;310:71-76.
89. Ali MY, Gopal KV, Llerena LA, et al. Hypercalcemia associated with infection by Cryptococcus neoformans and Coccidioides immitis. Am J Med Sci. 1999;310:71-76.
90. Schambelan M, Mulligan K, Grunfeld C, et al. Recombinant growth hormone in patients with HIV-associated wasting. A randomised placebo-controlled trial. Serostim study group. Ann Intern Med. 1996;125:873-882.
91. Bruns ME, Vollmer SS, Bruns DE, et al. Human growth hormone increases intestinal vitamin D dependent calcium binding protein in hypophysectomised rats. Endocrinology. 1983;113:1387-1392.
92. Lancer SR, Bowser EN, Hargis GK. The effect of growth hormone on parathyroid function in rats. Endocrinology. 1976;98:1289-1293.
93. Welch K, Finkbeiner W, Alpers CE, et al. Autopsy findings in the acquired immune deficiency syndrome. JAMA. 1984;252:1152-1159.
94. Hellman P, Albert J, Gidlung M, et al. Impaired parathyroid hormone release in human immunodeficiency syndrome. J Natl Med Assoc. 1994;84:626-628.
95. Jaeger P, Otto S, Speck RF, et al. Altered parathyroid gland function in severely immunocompromised patients infected with human immunodeficiency virus. J Clin Endocrinol Metab. 1994;79:1701-1705
96. Zaloga GP, Chernow B. The multifactorial basis for hypocalcemia during sepsis: studies of parathyroid hormone-vitamin D axis. Ann Intern Med. 1987;107:36-41.
97. Hellman P, Karlsson-Parra A, Klareskog L, et al. Expression and function of a CD4-like molecule in parathyroid tissue. Surgery. 1996;120:985-992.
98. Lehman R, Leuzinger B, Solomon F. Symptomatic hypoparathyroidism in acquired immunodeficiency syndrome. Horm Res. 1994;42:295-299.
99. Hoy J, Hudson J, Law M, et al. Osteopenia in a randomised multicentre study of protease inhibitor substitution in patients with lipodystrophy syndrome and well controlled HIV viraemia: extended follow up to 48 weeks [abstract P32]. In: 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; Toronto; September 13-15, 2000.
100. Grinspoon S, Corcoran C, Parlman K et al. Effect of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomised controlled trial. Ann Intern Med. 2000;133:348-355.
101. Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 2003;36:482-490
102. Mondy K, Tebas P. Emerging bone problems in patients infected with human immunodeficiency virus. Clin Infect Dis. 2003;36 (suppl 2):S101-S105.
103. Consensus Development Conference. Diagnoses prophylaxis treatment of osteoporosis. Am J Med. 1991;90:107-110.
104. Consensus Development Conference. Diagnoses prophylaxis treatment of osteoporosis. Am J Med. 1993;94:646-650.
105. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis [technical report series 843]. Geneva: WHO, 1994.
106. Department of Health. Quick Reference Primary Guide on the Prevention and Treatment of Osteoporosis. London: Department of Health, 1998.